Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
A recent analysis suggested that only one in four people on antiretroviral treatment take 95% or more of their doses.
ViiV applies for FDA approval of HIV drug fostemsavir
In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.
Gilead’s HIV capsid inhibitor might need dosing only every six months
A recent survey found that pharmacies are insufficiently educating the public about unused opioid and antibiotic disposal.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
However, because this combo is not as effective as the current standard treatment, the search for new options continues.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.